Eric Poeschla
Concepts (504)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunodeficiency Virus, Feline | 27 | 2023 | 30 | 7.500 |
Why?
| HIV-1 | 38 | 2022 | 776 | 5.170 |
Why?
| Genetic Vectors | 27 | 2013 | 302 | 4.570 |
Why?
| Virus Integration | 20 | 2022 | 71 | 3.240 |
Why?
| HIV Integrase | 14 | 2022 | 66 | 2.880 |
Why?
| Virus Replication | 28 | 2022 | 405 | 2.880 |
Why?
| Intercellular Signaling Peptides and Proteins | 14 | 2022 | 369 | 2.300 |
Why?
| Cats | 24 | 2023 | 205 | 2.270 |
Why?
| RNA, Viral | 11 | 2020 | 572 | 2.210 |
Why?
| Lentiviruses, Primate | 4 | 2023 | 13 | 2.120 |
Why?
| Lentivirus | 12 | 2022 | 52 | 2.090 |
Why?
| Genetic Therapy | 13 | 2013 | 267 | 1.650 |
Why?
| DNA, Viral | 7 | 2022 | 356 | 1.630 |
Why?
| Immunity, Innate | 7 | 2020 | 745 | 1.570 |
Why?
| Picornaviridae | 3 | 2020 | 18 | 1.510 |
Why?
| Interferon-Induced Helicase, IFIH1 | 2 | 2020 | 14 | 1.490 |
Why?
| Cell Line | 34 | 2020 | 2707 | 1.480 |
Why?
| Chromatin | 9 | 2016 | 441 | 1.440 |
Why?
| Reverse Transcription | 4 | 2021 | 19 | 1.270 |
Why?
| Antibodies, Viral | 2 | 2020 | 542 | 1.180 |
Why?
| Lentivirus Infections | 4 | 2014 | 7 | 1.100 |
Why?
| RNA Interference | 8 | 2020 | 460 | 1.100 |
Why?
| Retroviridae | 5 | 2022 | 89 | 1.090 |
Why?
| Gene Transfer Techniques | 10 | 2011 | 154 | 1.060 |
Why?
| Gene Products, gag | 3 | 2012 | 38 | 1.040 |
Why?
| HIV Infections | 15 | 2022 | 2459 | 1.020 |
Why?
| Adaptor Proteins, Signal Transducing | 7 | 2020 | 394 | 1.010 |
Why?
| Integrases | 5 | 2022 | 123 | 0.940 |
Why?
| Virus Assembly | 5 | 2014 | 67 | 0.930 |
Why?
| Trabecular Meshwork | 8 | 2014 | 75 | 0.920 |
Why?
| Interferons | 2 | 2022 | 151 | 0.890 |
Why?
| Capsid | 7 | 2022 | 77 | 0.840 |
Why?
| Transgenes | 8 | 2009 | 174 | 0.840 |
Why?
| Aqueous Humor | 6 | 2009 | 31 | 0.830 |
Why?
| Animals | 56 | 2023 | 33381 | 0.830 |
Why?
| Host-Pathogen Interactions | 6 | 2021 | 300 | 0.820 |
Why?
| Virion | 6 | 2022 | 78 | 0.780 |
Why?
| Spumavirus | 1 | 2020 | 2 | 0.770 |
Why?
| Gammaretrovirus | 1 | 2020 | 2 | 0.770 |
Why?
| Recombinant Fusion Proteins | 6 | 2011 | 653 | 0.740 |
Why?
| Teicoplanin | 1 | 2020 | 17 | 0.730 |
Why?
| Chiroptera | 1 | 2020 | 50 | 0.720 |
Why?
| HIV | 6 | 2012 | 210 | 0.720 |
Why?
| Antibodies, Neutralizing | 2 | 2022 | 228 | 0.720 |
Why?
| Prisons | 1 | 2020 | 74 | 0.710 |
Why?
| Transcription Factors | 7 | 2020 | 1570 | 0.710 |
Why?
| Liver Diseases, Parasitic | 1 | 2019 | 2 | 0.700 |
Why?
| Gram-Positive Bacterial Infections | 1 | 2020 | 67 | 0.700 |
Why?
| Fascioliasis | 1 | 2019 | 6 | 0.690 |
Why?
| Molecular Sequence Data | 17 | 2014 | 2871 | 0.680 |
Why?
| Humans | 92 | 2022 | 118972 | 0.660 |
Why?
| Exodeoxyribonucleases | 1 | 2018 | 22 | 0.660 |
Why?
| Nucleotidyltransferases | 1 | 2018 | 25 | 0.660 |
Why?
| CD4-Positive T-Lymphocytes | 5 | 2014 | 984 | 0.650 |
Why?
| Retroviridae Infections | 3 | 2020 | 46 | 0.650 |
Why?
| Pneumonia, Viral | 2 | 2020 | 348 | 0.640 |
Why?
| Coronavirus Infections | 2 | 2020 | 339 | 0.640 |
Why?
| Amino Acid Sequence | 10 | 2023 | 2071 | 0.620 |
Why?
| Dyspnea | 1 | 2019 | 201 | 0.610 |
Why?
| Ferrets | 2 | 2020 | 21 | 0.610 |
Why?
| Outpatients | 1 | 2020 | 325 | 0.590 |
Why?
| Betacoronavirus | 1 | 2020 | 254 | 0.590 |
Why?
| Eosinophilia | 1 | 2019 | 184 | 0.590 |
Why?
| Transformation, Genetic | 2 | 2012 | 15 | 0.590 |
Why?
| Phosphoproteins | 1 | 2018 | 308 | 0.560 |
Why?
| mRNA Cleavage and Polyadenylation Factors | 4 | 2020 | 28 | 0.550 |
Why?
| Viral Load | 3 | 2020 | 419 | 0.540 |
Why?
| Antibodies, Monoclonal | 2 | 2020 | 1284 | 0.540 |
Why?
| Nuclear Pore Complex Proteins | 2 | 2020 | 34 | 0.530 |
Why?
| Pandemics | 2 | 2020 | 1355 | 0.520 |
Why?
| Gene Knockout Techniques | 2 | 2014 | 105 | 0.510 |
Why?
| DNA, Complementary | 2 | 2013 | 268 | 0.500 |
Why?
| Cat Diseases | 1 | 2014 | 15 | 0.480 |
Why?
| Cytosine Deaminase | 2 | 2010 | 14 | 0.480 |
Why?
| HIV Integrase Inhibitors | 4 | 2022 | 60 | 0.470 |
Why?
| Viral Envelope Proteins | 1 | 2014 | 80 | 0.460 |
Why?
| Transduction, Genetic | 5 | 2008 | 116 | 0.460 |
Why?
| Glaucoma | 2 | 2009 | 202 | 0.450 |
Why?
| Animals, Genetically Modified | 2 | 2011 | 225 | 0.440 |
Why?
| Molecular Chaperones | 1 | 2014 | 174 | 0.440 |
Why?
| RNA-Binding Proteins | 2 | 2014 | 371 | 0.410 |
Why?
| Lentiviruses, Feline | 1 | 2011 | 1 | 0.410 |
Why?
| Carnivora | 1 | 2011 | 7 | 0.410 |
Why?
| Mice | 19 | 2020 | 15520 | 0.410 |
Why?
| Primate Diseases | 1 | 2011 | 5 | 0.410 |
Why?
| Open Reading Frames | 1 | 2012 | 121 | 0.400 |
Why?
| Monkey Diseases | 1 | 2011 | 21 | 0.400 |
Why?
| Mutation | 9 | 2020 | 3457 | 0.400 |
Why?
| Nuclear Localization Signals | 3 | 2006 | 14 | 0.400 |
Why?
| Antigens, CD | 1 | 2014 | 460 | 0.400 |
Why?
| Cells, Cultured | 10 | 2012 | 4077 | 0.390 |
Why?
| Gene Products, vif | 1 | 2010 | 2 | 0.380 |
Why?
| Cell Nucleus | 5 | 2021 | 580 | 0.380 |
Why?
| Anti-Bacterial Agents | 1 | 2020 | 1510 | 0.380 |
Why?
| Nerve Tissue Proteins | 1 | 2014 | 551 | 0.370 |
Why?
| Cytidine Deaminase | 1 | 2010 | 57 | 0.370 |
Why?
| Disease Models, Animal | 5 | 2013 | 3730 | 0.370 |
Why?
| Active Transport, Cell Nucleus | 6 | 2022 | 113 | 0.370 |
Why?
| Intraocular Pressure | 2 | 2009 | 275 | 0.360 |
Why?
| DNA Viruses | 1 | 2009 | 10 | 0.360 |
Why?
| Prostaglandins | 1 | 2009 | 78 | 0.360 |
Why?
| Purines | 1 | 2010 | 161 | 0.350 |
Why?
| Eye Proteins | 4 | 2014 | 77 | 0.350 |
Why?
| Gene Knockdown Techniques | 2 | 2016 | 311 | 0.340 |
Why?
| Gene Expression | 8 | 2013 | 1489 | 0.330 |
Why?
| Proteasome Endopeptidase Complex | 2 | 2009 | 139 | 0.330 |
Why?
| Green Fluorescent Proteins | 6 | 2011 | 395 | 0.320 |
Why?
| Cytoplasm | 5 | 2021 | 269 | 0.320 |
Why?
| Base Sequence | 9 | 2012 | 2159 | 0.310 |
Why?
| Primates | 3 | 2020 | 114 | 0.310 |
Why?
| Transfection | 5 | 2012 | 888 | 0.310 |
Why?
| Biological Evolution | 1 | 2011 | 443 | 0.310 |
Why?
| HEK293 Cells | 5 | 2020 | 625 | 0.300 |
Why?
| Retina | 3 | 2004 | 278 | 0.290 |
Why?
| Antiviral Agents | 3 | 2022 | 654 | 0.280 |
Why?
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2005 | 2 | 0.280 |
Why?
| Gene Targeting | 2 | 2004 | 80 | 0.280 |
Why?
| Mice, Transgenic | 3 | 2020 | 2025 | 0.280 |
Why?
| Protein Binding | 8 | 2021 | 1975 | 0.270 |
Why?
| HIV-2 | 4 | 2002 | 15 | 0.270 |
Why?
| Anti-HIV Agents | 2 | 2022 | 664 | 0.260 |
Why?
| Proteins | 3 | 2007 | 938 | 0.260 |
Why?
| Oncogenic Viruses | 1 | 2004 | 3 | 0.260 |
Why?
| Genes, Reporter | 4 | 2012 | 270 | 0.250 |
Why?
| HeLa Cells | 7 | 2020 | 583 | 0.250 |
Why?
| Cell Culture Techniques | 3 | 2012 | 356 | 0.240 |
Why?
| Lymphocytes | 4 | 2012 | 347 | 0.240 |
Why?
| Pigment Epithelium of Eye | 1 | 2003 | 34 | 0.240 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2020 | 982 | 0.240 |
Why?
| Acquired Immunodeficiency Syndrome | 2 | 1996 | 224 | 0.240 |
Why?
| Anti-Retroviral Agents | 1 | 2005 | 208 | 0.230 |
Why?
| Bone Marrow Stromal Antigen 2 | 1 | 2023 | 2 | 0.230 |
Why?
| Human Immunodeficiency Virus Proteins | 1 | 2023 | 6 | 0.230 |
Why?
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 94 | 0.230 |
Why?
| Protein Sorting Signals | 1 | 2023 | 15 | 0.230 |
Why?
| Protein Structure, Tertiary | 5 | 2015 | 823 | 0.230 |
Why?
| Viral Regulatory and Accessory Proteins | 1 | 2023 | 28 | 0.230 |
Why?
| Evolution, Molecular | 3 | 2020 | 454 | 0.230 |
Why?
| Amino Acids | 2 | 2023 | 464 | 0.230 |
Why?
| GPI-Linked Proteins | 1 | 2023 | 56 | 0.230 |
Why?
| RNA, Catalytic | 5 | 1998 | 182 | 0.220 |
Why?
| Mutation, Missense | 2 | 2014 | 300 | 0.220 |
Why?
| RNA, Small Interfering | 2 | 2020 | 564 | 0.220 |
Why?
| Karyopherins | 2 | 2012 | 17 | 0.220 |
Why?
| Cytoskeletal Proteins | 3 | 2008 | 146 | 0.220 |
Why?
| Gene Products, env | 3 | 2012 | 13 | 0.210 |
Why?
| Aotidae | 2 | 2020 | 7 | 0.210 |
Why?
| Genetic Engineering | 1 | 2003 | 83 | 0.210 |
Why?
| Virus Cultivation | 2 | 2012 | 25 | 0.210 |
Why?
| Tripartite Motif Proteins | 2 | 2020 | 31 | 0.210 |
Why?
| Cytomegalovirus | 3 | 2012 | 144 | 0.210 |
Why?
| Promoter Regions, Genetic | 4 | 2012 | 1158 | 0.210 |
Why?
| Dogs | 2 | 2014 | 371 | 0.200 |
Why?
| Genome, Viral | 4 | 2019 | 124 | 0.200 |
Why?
| Glycoproteins | 3 | 2008 | 319 | 0.200 |
Why?
| Receptors, Cytoplasmic and Nuclear | 2 | 2012 | 195 | 0.190 |
Why?
| Cyclophilin A | 1 | 2020 | 24 | 0.190 |
Why?
| Drug Resistance, Viral | 2 | 2014 | 98 | 0.190 |
Why?
| 3T3 Cells | 1 | 2020 | 141 | 0.190 |
Why?
| Immunologic Surveillance | 1 | 2020 | 19 | 0.190 |
Why?
| Pathogen-Associated Molecular Pattern Molecules | 1 | 2020 | 6 | 0.190 |
Why?
| Emigration and Immigration | 1 | 2020 | 47 | 0.190 |
Why?
| Receptor, Interferon alpha-beta | 1 | 2020 | 22 | 0.190 |
Why?
| Hantavirus Pulmonary Syndrome | 1 | 2020 | 3 | 0.190 |
Why?
| Terminal Repeat Sequences | 1 | 2020 | 13 | 0.190 |
Why?
| Vesicular Transport Proteins | 1 | 2021 | 84 | 0.190 |
Why?
| Disease Resistance | 1 | 2020 | 29 | 0.180 |
Why?
| Quarantine | 1 | 2020 | 25 | 0.180 |
Why?
| Growth Inhibitors | 2 | 2013 | 43 | 0.180 |
Why?
| Immune Evasion | 1 | 2020 | 48 | 0.180 |
Why?
| Endogenous Retroviruses | 1 | 2020 | 19 | 0.180 |
Why?
| Immunoassay | 1 | 2020 | 101 | 0.180 |
Why?
| RNA Virus Infections | 1 | 2019 | 11 | 0.180 |
Why?
| Interferon-beta | 1 | 2020 | 82 | 0.180 |
Why?
| RNA, Double-Stranded | 1 | 2019 | 46 | 0.180 |
Why?
| RNA Viruses | 1 | 2019 | 28 | 0.180 |
Why?
| Ciliary Body | 2 | 2009 | 33 | 0.180 |
Why?
| Immunoblotting | 2 | 2014 | 307 | 0.180 |
Why?
| Delayed-Action Preparations | 1 | 2020 | 161 | 0.170 |
Why?
| Viremia | 1 | 2020 | 132 | 0.170 |
Why?
| Immunity, Humoral | 1 | 2020 | 117 | 0.170 |
Why?
| Embryonic Development | 1 | 2020 | 118 | 0.170 |
Why?
| Interferon Type I | 1 | 2020 | 129 | 0.170 |
Why?
| Sequence Alignment | 2 | 2014 | 336 | 0.170 |
Why?
| Cell Transformation, Viral | 1 | 1998 | 22 | 0.170 |
Why?
| THP-1 Cells | 1 | 2018 | 20 | 0.170 |
Why?
| Luminescent Proteins | 3 | 2012 | 174 | 0.170 |
Why?
| Monocytes | 2 | 2018 | 513 | 0.170 |
Why?
| Emigrants and Immigrants | 1 | 2020 | 115 | 0.160 |
Why?
| Afghanistan | 1 | 2019 | 108 | 0.160 |
Why?
| Gene Expression Regulation, Developmental | 2 | 2020 | 814 | 0.160 |
Why?
| Receptors, CXCR4 | 1 | 1998 | 81 | 0.160 |
Why?
| Residence Characteristics | 1 | 2020 | 299 | 0.160 |
Why?
| RNA, Messenger | 3 | 2020 | 2657 | 0.160 |
Why?
| Renal Insufficiency | 1 | 2020 | 150 | 0.160 |
Why?
| Genes, vif | 2 | 2010 | 3 | 0.160 |
Why?
| T-Lymphocytes | 5 | 2020 | 1774 | 0.160 |
Why?
| Protein Transport | 2 | 2012 | 412 | 0.150 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2020 | 227 | 0.150 |
Why?
| Viral Proteins | 2 | 2015 | 296 | 0.150 |
Why?
| Rats | 7 | 2014 | 5392 | 0.150 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2020 | 368 | 0.150 |
Why?
| Quinolines | 2 | 2014 | 128 | 0.150 |
Why?
| Genes, Immediate-Early | 2 | 2012 | 17 | 0.150 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 453 | 0.140 |
Why?
| Public Health | 1 | 2020 | 450 | 0.140 |
Why?
| Genes, Viral | 1 | 2015 | 93 | 0.140 |
Why?
| Plasmids | 4 | 2012 | 355 | 0.140 |
Why?
| Kinetics | 6 | 2013 | 1624 | 0.140 |
Why?
| Epigenesis, Genetic | 1 | 2020 | 539 | 0.130 |
Why?
| Female | 15 | 2020 | 61564 | 0.130 |
Why?
| Species Specificity | 2 | 2012 | 565 | 0.130 |
Why?
| Blotting, Western | 5 | 2015 | 1194 | 0.130 |
Why?
| Healthcare Disparities | 1 | 2020 | 496 | 0.130 |
Why?
| Transcription, Genetic | 3 | 2016 | 1323 | 0.130 |
Why?
| Echinocandins | 1 | 2014 | 8 | 0.130 |
Why?
| rhoA GTP-Binding Protein | 1 | 2014 | 80 | 0.130 |
Why?
| Gene Products, rev | 2 | 2004 | 5 | 0.130 |
Why?
| Mucormycosis | 1 | 2014 | 20 | 0.120 |
Why?
| Amphotericin B | 1 | 2014 | 31 | 0.120 |
Why?
| beta-Galactosidase | 2 | 2004 | 65 | 0.120 |
Why?
| Voriconazole | 1 | 2014 | 24 | 0.120 |
Why?
| Acetates | 1 | 2014 | 98 | 0.120 |
Why?
| Gene Expression Regulation | 1 | 2003 | 2445 | 0.120 |
Why?
| Cyclophilins | 1 | 2014 | 29 | 0.120 |
Why?
| Ocular Hypertension | 1 | 2014 | 60 | 0.120 |
Why?
| Polymerase Chain Reaction | 2 | 2014 | 1012 | 0.120 |
Why?
| Antifungal Agents | 1 | 2014 | 134 | 0.120 |
Why?
| Introns | 3 | 2015 | 234 | 0.120 |
Why?
| Retroviridae Proteins | 2 | 2012 | 12 | 0.110 |
Why?
| Mice, Knockout | 3 | 2015 | 2680 | 0.110 |
Why?
| Protein Multimerization | 1 | 2014 | 161 | 0.110 |
Why?
| Rats, Sprague-Dawley | 4 | 2014 | 2478 | 0.110 |
Why?
| Mice, Inbred C57BL | 2 | 2020 | 4908 | 0.110 |
Why?
| Vero Cells | 2 | 2019 | 69 | 0.110 |
Why?
| F-Box Proteins | 1 | 2012 | 20 | 0.110 |
Why?
| DNA-Binding Proteins | 3 | 2013 | 1346 | 0.110 |
Why?
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 12 | 0.110 |
Why?
| Collagen | 1 | 2014 | 433 | 0.110 |
Why?
| Genes, env | 1 | 2012 | 5 | 0.110 |
Why?
| Genes, Synthetic | 1 | 2012 | 14 | 0.110 |
Why?
| Mink | 1 | 2011 | 12 | 0.110 |
Why?
| Antigens, Neoplasm | 1 | 2013 | 228 | 0.100 |
Why?
| Feline Acquired Immunodeficiency Syndrome | 1 | 2011 | 1 | 0.100 |
Why?
| Male | 12 | 2020 | 57801 | 0.100 |
Why?
| Rabbits | 2 | 2011 | 780 | 0.100 |
Why?
| Caspase 8 | 1 | 2011 | 47 | 0.100 |
Why?
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2011 | 15 | 0.100 |
Why?
| bcl-2-Associated X Protein | 1 | 2011 | 46 | 0.100 |
Why?
| Histidine | 2 | 2014 | 63 | 0.100 |
Why?
| Macrophages | 3 | 2009 | 1324 | 0.100 |
Why?
| Jurkat Cells | 3 | 2020 | 134 | 0.100 |
Why?
| DNA | 3 | 2005 | 1388 | 0.100 |
Why?
| Signal Transduction | 2 | 2020 | 4709 | 0.100 |
Why?
| APOBEC-3G Deaminase | 1 | 2010 | 6 | 0.100 |
Why?
| vif Gene Products, Human Immunodeficiency Virus | 1 | 2010 | 4 | 0.090 |
Why?
| Injections | 2 | 2009 | 167 | 0.090 |
Why?
| Virus Internalization | 1 | 2010 | 41 | 0.090 |
Why?
| Polyradiculoneuropathy | 1 | 2009 | 3 | 0.090 |
Why?
| Young Adult | 4 | 2020 | 10793 | 0.090 |
Why?
| Neoplasms | 2 | 2013 | 2179 | 0.090 |
Why?
| Autoimmune Diseases of the Nervous System | 1 | 2009 | 19 | 0.090 |
Why?
| Swine | 2 | 2009 | 730 | 0.090 |
Why?
| Iris | 1 | 2009 | 19 | 0.090 |
Why?
| Isoenzymes | 1 | 2010 | 297 | 0.090 |
Why?
| Macaca fascicularis | 1 | 2009 | 53 | 0.090 |
Why?
| Protein Processing, Post-Translational | 2 | 2004 | 408 | 0.090 |
Why?
| Cyclooxygenase 2 | 1 | 2009 | 168 | 0.090 |
Why?
| Endosomes | 1 | 2010 | 128 | 0.090 |
Why?
| Intracellular Fluid | 1 | 2008 | 26 | 0.080 |
Why?
| Saccharomyces cerevisiae | 1 | 2013 | 495 | 0.080 |
Why?
| United States | 3 | 2020 | 12555 | 0.080 |
Why?
| Recombinant Proteins | 2 | 2009 | 1308 | 0.080 |
Why?
| Antigens, Viral | 1 | 2009 | 181 | 0.080 |
Why?
| Infectious Anemia Virus, Equine | 1 | 2007 | 1 | 0.080 |
Why?
| Cell Division | 2 | 2001 | 776 | 0.080 |
Why?
| Ubiquitin-Protein Ligases | 2 | 2007 | 148 | 0.080 |
Why?
| Occupational Diseases | 1 | 2009 | 136 | 0.080 |
Why?
| rev Gene Products, Human Immunodeficiency Virus | 2 | 2004 | 5 | 0.080 |
Why?
| Glaucoma, Open-Angle | 1 | 2009 | 95 | 0.080 |
Why?
| Antigens, CD34 | 2 | 1998 | 98 | 0.080 |
Why?
| Phylogeny | 1 | 2011 | 816 | 0.080 |
Why?
| Leukocytes, Mononuclear | 1 | 2010 | 509 | 0.080 |
Why?
| Cell Membrane | 3 | 2010 | 710 | 0.080 |
Why?
| Gene Products, pol | 2 | 1998 | 6 | 0.070 |
Why?
| Virulence | 1 | 2007 | 240 | 0.070 |
Why?
| Models, Genetic | 1 | 2009 | 595 | 0.070 |
Why?
| Occupational Exposure | 1 | 2009 | 277 | 0.070 |
Why?
| Crystallography, X-Ray | 2 | 2020 | 422 | 0.070 |
Why?
| Binding Sites | 2 | 2021 | 1224 | 0.070 |
Why?
| Chromosomes, Human | 1 | 2006 | 41 | 0.070 |
Why?
| Retinal Ganglion Cells | 2 | 2004 | 92 | 0.070 |
Why?
| Time Factors | 2 | 2009 | 6412 | 0.070 |
Why?
| Oxidative Stress | 1 | 2012 | 1178 | 0.070 |
Why?
| Sequence Deletion | 1 | 2006 | 171 | 0.070 |
Why?
| Image Processing, Computer-Assisted | 1 | 2010 | 709 | 0.070 |
Why?
| Organ Culture Techniques | 2 | 2006 | 149 | 0.070 |
Why?
| Avian Leukosis Virus | 1 | 2005 | 7 | 0.070 |
Why?
| Models, Biological | 1 | 2013 | 1715 | 0.070 |
Why?
| Cell Survival | 1 | 2009 | 1047 | 0.070 |
Why?
| Mitochondria | 1 | 2011 | 786 | 0.070 |
Why?
| Genes, Regulator | 1 | 2005 | 33 | 0.070 |
Why?
| Leukemia Virus, Gibbon Ape | 1 | 2005 | 1 | 0.070 |
Why?
| Protein Structure, Secondary | 1 | 2006 | 338 | 0.070 |
Why?
| Peptide Fragments | 1 | 2009 | 702 | 0.060 |
Why?
| Genes, gag | 1 | 2004 | 3 | 0.060 |
Why?
| NIH 3T3 Cells | 1 | 2005 | 139 | 0.060 |
Why?
| Nuclear Proteins | 1 | 2009 | 597 | 0.060 |
Why?
| Proteasome Inhibitors | 1 | 2004 | 44 | 0.060 |
Why?
| Ribonucleases | 1 | 2004 | 53 | 0.060 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2006 | 260 | 0.060 |
Why?
| Indicators and Reagents | 1 | 2004 | 100 | 0.060 |
Why?
| Ubiquitin | 1 | 2004 | 66 | 0.060 |
Why?
| Genes, vpu | 1 | 2004 | 1 | 0.060 |
Why?
| Hematopoietic Stem Cells | 2 | 1998 | 359 | 0.060 |
Why?
| Immunoprecipitation | 1 | 2004 | 161 | 0.060 |
Why?
| Histones | 1 | 2009 | 552 | 0.060 |
Why?
| Protease Inhibitors | 1 | 2004 | 102 | 0.060 |
Why?
| Models, Molecular | 2 | 2022 | 1435 | 0.060 |
Why?
| Genetic Predisposition to Disease | 1 | 2012 | 2275 | 0.060 |
Why?
| Alleles | 2 | 2020 | 832 | 0.060 |
Why?
| Digestive System Diseases | 1 | 2003 | 27 | 0.060 |
Why?
| Gene Expression Regulation, Viral | 1 | 2004 | 84 | 0.060 |
Why?
| Microscopy, Confocal | 1 | 2004 | 314 | 0.060 |
Why?
| Adenoviridae | 1 | 2004 | 191 | 0.060 |
Why?
| Carrier Proteins | 1 | 2007 | 726 | 0.060 |
Why?
| Virus Uncoating | 1 | 2022 | 1 | 0.060 |
Why?
| Eye Diseases | 1 | 2003 | 77 | 0.060 |
Why?
| Microscopy, Fluorescence | 1 | 2004 | 412 | 0.060 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2004 | 290 | 0.050 |
Why?
| Cell Cycle | 1 | 2005 | 550 | 0.050 |
Why?
| Aphidicolin | 1 | 2001 | 6 | 0.050 |
Why?
| Capsid Proteins | 1 | 2022 | 70 | 0.050 |
Why?
| Respiratory Tract Diseases | 1 | 2003 | 143 | 0.050 |
Why?
| Leukemia Virus, Murine | 1 | 2001 | 16 | 0.050 |
Why?
| Lac Operon | 1 | 2001 | 47 | 0.050 |
Why?
| Middle Aged | 6 | 2020 | 27617 | 0.050 |
Why?
| Apoptosis | 1 | 2011 | 2484 | 0.050 |
Why?
| Catalytic Domain | 1 | 2022 | 206 | 0.050 |
Why?
| Nuclear Pore | 1 | 2021 | 14 | 0.050 |
Why?
| Osteoblasts | 1 | 2002 | 115 | 0.050 |
Why?
| Organ Specificity | 1 | 2001 | 278 | 0.050 |
Why?
| Deuterium Exchange Measurement | 1 | 2020 | 30 | 0.050 |
Why?
| Breast Neoplasms | 1 | 2012 | 1965 | 0.050 |
Why?
| Amino Acid Motifs | 1 | 2021 | 200 | 0.050 |
Why?
| Nervous System Diseases | 1 | 2003 | 261 | 0.050 |
Why?
| Nuclear Respiratory Factor 1 | 1 | 2020 | 3 | 0.050 |
Why?
| Horses | 1 | 2020 | 106 | 0.050 |
Why?
| Macaca mulatta | 1 | 2020 | 153 | 0.050 |
Why?
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 13 | 0.050 |
Why?
| HCT116 Cells | 1 | 2020 | 68 | 0.050 |
Why?
| Neurons | 2 | 1998 | 1345 | 0.050 |
Why?
| Cryoelectron Microscopy | 1 | 2020 | 139 | 0.050 |
Why?
| Travel | 1 | 2020 | 116 | 0.040 |
Why?
| Structure-Activity Relationship | 1 | 2021 | 522 | 0.040 |
Why?
| Proteinuria | 1 | 2020 | 99 | 0.040 |
Why?
| Sheep | 1 | 2022 | 764 | 0.040 |
Why?
| Protein Domains | 1 | 2020 | 212 | 0.040 |
Why?
| Immunohistochemistry | 2 | 2015 | 1691 | 0.040 |
Why?
| Giant Cells | 1 | 1998 | 22 | 0.040 |
Why?
| Needs Assessment | 1 | 2020 | 327 | 0.040 |
Why?
| Rodentia | 1 | 1998 | 47 | 0.040 |
Why?
| Health Status Disparities | 1 | 2020 | 209 | 0.040 |
Why?
| RNA-Directed DNA Polymerase | 1 | 1998 | 34 | 0.040 |
Why?
| Aged | 4 | 2020 | 19657 | 0.040 |
Why?
| Coculture Techniques | 1 | 1998 | 208 | 0.040 |
Why?
| Drug Therapy, Combination | 2 | 2014 | 965 | 0.040 |
Why?
| Mutagenesis | 1 | 1998 | 176 | 0.040 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 103 | 0.040 |
Why?
| Brain | 1 | 2009 | 2490 | 0.040 |
Why?
| Cattle | 1 | 2020 | 978 | 0.040 |
Why?
| Gene Deletion | 1 | 1998 | 361 | 0.040 |
Why?
| Age Factors | 1 | 2003 | 2995 | 0.040 |
Why?
| RNA | 1 | 2022 | 833 | 0.030 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2020 | 632 | 0.030 |
Why?
| Diagnosis, Differential | 1 | 2020 | 1384 | 0.030 |
Why?
| DNA Methylation | 1 | 2020 | 503 | 0.030 |
Why?
| In Situ Hybridization | 1 | 2015 | 311 | 0.030 |
Why?
| Cell Line, Tumor | 2 | 2013 | 2851 | 0.030 |
Why?
| AIDS Vaccines | 1 | 1995 | 44 | 0.030 |
Why?
| Receptors, Purinergic | 3 | 1990 | 19 | 0.030 |
Why?
| Mutant Proteins | 1 | 2014 | 100 | 0.030 |
Why?
| RNA Splicing | 1 | 2015 | 243 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 333 | 0.030 |
Why?
| Amino Acid Substitution | 1 | 2014 | 276 | 0.030 |
Why?
| Vesicular stomatitis Indiana virus | 1 | 2013 | 13 | 0.030 |
Why?
| History, 21st Century | 1 | 2014 | 170 | 0.030 |
Why?
| Virus Diseases | 1 | 2015 | 198 | 0.030 |
Why?
| Topoisomerase II Inhibitors | 1 | 2013 | 23 | 0.030 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 770 | 0.030 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 827 | 0.030 |
Why?
| DNA Topoisomerases, Type II | 1 | 2013 | 45 | 0.030 |
Why?
| Galactose | 1 | 2013 | 20 | 0.030 |
Why?
| Fungi | 1 | 2014 | 123 | 0.030 |
Why?
| Tumor Escape | 1 | 2013 | 38 | 0.030 |
Why?
| L-Lactate Dehydrogenase | 1 | 2013 | 112 | 0.030 |
Why?
| Succinate Dehydrogenase | 1 | 2013 | 44 | 0.030 |
Why?
| Gene Library | 1 | 2013 | 127 | 0.030 |
Why?
| Immunotherapy, Adoptive | 1 | 1995 | 191 | 0.030 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 2012 | 155 | 0.030 |
Why?
| Antibiotics, Antineoplastic | 1 | 2013 | 114 | 0.030 |
Why?
| Serine-Arginine Splicing Factors | 1 | 2012 | 20 | 0.030 |
Why?
| Immunotherapy | 2 | 2013 | 493 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2013 | 180 | 0.030 |
Why?
| Receptors, Cell Surface | 2 | 1984 | 367 | 0.030 |
Why?
| Molecular Conformation | 1 | 2012 | 146 | 0.030 |
Why?
| Paraganglioma | 1 | 2013 | 48 | 0.030 |
Why?
| Doxorubicin | 1 | 2013 | 302 | 0.030 |
Why?
| Cardiovascular Diseases | 1 | 2003 | 1798 | 0.030 |
Why?
| Protein Conformation | 1 | 2014 | 848 | 0.030 |
Why?
| DNA Primers | 1 | 2012 | 533 | 0.030 |
Why?
| Caspase 9 | 1 | 2011 | 50 | 0.030 |
Why?
| Risk Assessment | 1 | 2020 | 3057 | 0.020 |
Why?
| Epitopes | 1 | 2013 | 443 | 0.020 |
Why?
| Microscopy, Electron | 1 | 2011 | 413 | 0.020 |
Why?
| Adenosine | 2 | 1990 | 211 | 0.020 |
Why?
| Salt Gland | 1 | 1990 | 1 | 0.020 |
Why?
| Recurrence | 1 | 2013 | 975 | 0.020 |
Why?
| Abattoirs | 1 | 2009 | 2 | 0.020 |
Why?
| Adipose Tissue | 2 | 1984 | 606 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 1995 | 969 | 0.020 |
Why?
| Myelin Basic Protein | 1 | 2009 | 45 | 0.020 |
Why?
| Indiana | 1 | 2009 | 29 | 0.020 |
Why?
| Colorado | 1 | 2020 | 4196 | 0.020 |
Why?
| Air Pollutants, Occupational | 1 | 2009 | 33 | 0.020 |
Why?
| Chlorides | 1 | 1990 | 137 | 0.020 |
Why?
| Minnesota | 1 | 2009 | 137 | 0.020 |
Why?
| Cyclic AMP | 1 | 1990 | 242 | 0.020 |
Why?
| Adult | 3 | 2020 | 31512 | 0.020 |
Why?
| Repressor Proteins | 1 | 2012 | 377 | 0.020 |
Why?
| Inhalation Exposure | 1 | 2009 | 87 | 0.020 |
Why?
| Demyelinating Diseases | 1 | 2009 | 79 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2013 | 827 | 0.020 |
Why?
| Models, Theoretical | 1 | 2013 | 556 | 0.020 |
Why?
| Binding Sites, Antibody | 1 | 2008 | 38 | 0.020 |
Why?
| Drug Resistance, Neoplasm | 1 | 2013 | 671 | 0.020 |
Why?
| Cell Cycle Proteins | 1 | 2012 | 565 | 0.020 |
Why?
| Culture Media, Conditioned | 1 | 2008 | 112 | 0.020 |
Why?
| Aerosols | 1 | 2009 | 221 | 0.020 |
Why?
| Hybridomas | 1 | 2008 | 233 | 0.020 |
Why?
| Antibody Specificity | 1 | 2008 | 184 | 0.020 |
Why?
| Follow-Up Studies | 2 | 2009 | 4596 | 0.020 |
Why?
| Consensus Sequence | 1 | 2007 | 70 | 0.020 |
Why?
| Flow Cytometry | 1 | 2011 | 1085 | 0.020 |
Why?
| Eye | 1 | 2008 | 106 | 0.020 |
Why?
| Disease Outbreaks | 1 | 2009 | 322 | 0.020 |
Why?
| Drug Resistance, Multiple, Viral | 1 | 2006 | 11 | 0.020 |
Why?
| Melanoma | 1 | 2013 | 664 | 0.020 |
Why?
| HIV Protease Inhibitors | 1 | 2006 | 64 | 0.020 |
Why?
| Prostatic Neoplasms | 1 | 2013 | 940 | 0.020 |
Why?
| Aged, 80 and over | 2 | 2008 | 6561 | 0.020 |
Why?
| Microarray Analysis | 1 | 2005 | 124 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 2008 | 1206 | 0.020 |
Why?
| Treatment Failure | 1 | 2006 | 341 | 0.020 |
Why?
| Clinical Protocols | 2 | 1998 | 238 | 0.020 |
Why?
| Gene Silencing | 1 | 2005 | 177 | 0.020 |
Why?
| Phenotype | 1 | 2013 | 3003 | 0.020 |
Why?
| Ethylmaleimide | 1 | 1984 | 18 | 0.020 |
Why?
| Guanine Nucleotides | 1 | 1984 | 16 | 0.020 |
Why?
| Defective Viruses | 1 | 2004 | 4 | 0.020 |
Why?
| Codon | 1 | 2004 | 89 | 0.010 |
Why?
| PHEX Phosphate Regulating Neutral Endopeptidase | 1 | 2002 | 1 | 0.010 |
Why?
| Hypophosphatemia, Familial | 1 | 2002 | 3 | 0.010 |
Why?
| Photoreceptor Cells, Vertebrate | 1 | 2002 | 25 | 0.010 |
Why?
| Autoantibodies | 1 | 2009 | 1335 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 2006 | 1945 | 0.010 |
Why?
| Golgi Apparatus | 1 | 2002 | 91 | 0.010 |
Why?
| Growth Plate | 1 | 2002 | 34 | 0.010 |
Why?
| Adolescent | 1 | 2020 | 18480 | 0.010 |
Why?
| Blood Platelets | 1 | 1984 | 369 | 0.010 |
Why?
| Vitreous Body | 1 | 2002 | 104 | 0.010 |
Why?
| Mice, Inbred Strains | 1 | 2002 | 405 | 0.010 |
Why?
| Skull | 1 | 2002 | 127 | 0.010 |
Why?
| In Vitro Techniques | 3 | 1990 | 1094 | 0.010 |
Why?
| Endoplasmic Reticulum | 1 | 2002 | 241 | 0.010 |
Why?
| Animals, Newborn | 1 | 2002 | 806 | 0.010 |
Why?
| Lymphocyte Transfusion | 1 | 1998 | 19 | 0.010 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 1998 | 47 | 0.010 |
Why?
| Adenylyl Cyclases | 2 | 1990 | 86 | 0.010 |
Why?
| Skin | 1 | 2002 | 657 | 0.010 |
Why?
| Phenylisopropyladenosine | 2 | 1984 | 5 | 0.010 |
Why?
| Hydrolysis | 1 | 1995 | 176 | 0.010 |
Why?
| RNA Polymerase III | 1 | 1994 | 25 | 0.010 |
Why?
| Gentamicins | 1 | 1994 | 42 | 0.010 |
Why?
| RNA, Antisense | 1 | 1994 | 19 | 0.010 |
Why?
| Drug Resistance | 1 | 1994 | 167 | 0.010 |
Why?
| Selection, Genetic | 1 | 1994 | 252 | 0.010 |
Why?
| Treatment Outcome | 1 | 2006 | 9342 | 0.010 |
Why?
| 2-Chloroadenosine | 1 | 1990 | 3 | 0.010 |
Why?
| Dogfish | 1 | 1990 | 4 | 0.010 |
Why?
| Colforsin | 1 | 1990 | 55 | 0.010 |
Why?
| Somatostatin | 1 | 1990 | 53 | 0.010 |
Why?
| Theophylline | 1 | 1990 | 60 | 0.010 |
Why?
| Perfusion | 1 | 1990 | 153 | 0.010 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 1994 | 540 | 0.010 |
Why?
| Adenosine-5'-(N-ethylcarboxamide) | 1 | 1984 | 9 | 0.000 |
Why?
| Xanthines | 1 | 1984 | 15 | 0.000 |
Why?
| Tritium | 1 | 1984 | 70 | 0.000 |
Why?
| Radioligand Assay | 1 | 1984 | 45 | 0.000 |
Why?
| Guanosine Triphosphate | 1 | 1984 | 87 | 0.000 |
Why?
| Magnesium | 1 | 1984 | 150 | 0.000 |
Why?
| Sodium | 1 | 1984 | 200 | 0.000 |
Why?
| Vasodilator Agents | 1 | 1984 | 328 | 0.000 |
Why?
| Calcium | 1 | 1984 | 1169 | 0.000 |
Why?
|
|
Poeschla's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|